Oppenheimer analyst Matthew Biegler raised the price target on Fate Therapeutics (NASDAQ: FATE) to $135.00 (from $70.00) while maintaining an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE